Progression of histological lesions after ABO incompatible kidney transplantation.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2022
Historique:
received: 15 06 2022
accepted: 06 09 2022
entrez: 24 10 2022
pubmed: 25 10 2022
medline: 26 10 2022
Statut: epublish

Résumé

Recent large meta-analyses suggested a poorer long-term patients' and grafts' outcomes after ABO incompatible (ABOi) living-donor kidney transplantation (LDKT) compared to ABO compatible LDKT. However, little is known about the long-term histological pattern after ABOi LDKT. We compared the histological features observed on protocol biopsies from 03/11 to 11/19 in 94 ABOi LDKT (including 14 with preformed Donor Specific Antibodies, pDSAs), 27 LDKT ABO compatible (ABOc) with pDSAs, and 21 ABOc without pDSAs) during the first five years post transplantation. During the first 5 years post-transplantation, a progression of chronic lesions (patients with a ci >0 raised from 11% to 65%,

Identifiants

pubmed: 36275771
doi: 10.3389/fimmu.2022.969998
pmc: PMC9582152
doi:

Substances chimiques

ABO Blood-Group System 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

969998

Informations de copyright

Copyright © 2022 Guy, Delas, Esposito, Cointault, Colombat, Congy-Jolivet, Raynaud, Kamar and Del Bello.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Am J Kidney Dis. 2020 Nov;76(5):616-623
pubmed: 32668318
Kidney Int. 2017 Aug;92(2):461-469
pubmed: 28601198
Am J Transplant. 2018 Feb;18(2):293-307
pubmed: 29243394
Transplantation. 2012 Mar 27;93(6):603-9
pubmed: 22290268
Transplantation. 2015 Feb;99(2):400-4
pubmed: 25050471
Am J Transplant. 2010 Sep;10(9):2066-73
pubmed: 20883541
J Clin Apher. 2020 Sep;35(5):444-452
pubmed: 32805070
Nat Rev Nephrol. 2015 Dec;11(12):732-47
pubmed: 26324199
Clin J Am Soc Nephrol. 2018 Aug 7;13(8):1234-1243
pubmed: 30012630
Am J Kidney Dis. 2020 Nov;76(5):607-609
pubmed: 32771282
Transplantation. 2012 Feb 27;93(4):390-7
pubmed: 22222784
Transpl Int. 2022 Mar 23;35:10248
pubmed: 35401036
QJM. 2012 Dec;105(12):1141-50
pubmed: 22908321
Am J Transplant. 2012 Feb;12(2):388-99
pubmed: 22081892
Transplantation. 2014 Nov 27;98(10):1089-96
pubmed: 24911035
Transplantation. 2015 Feb;99(2):e8-9
pubmed: 25651124
Transpl Int. 2021 Dec;34(12):2706-2719
pubmed: 34687095
Transplantation. 2017 Jun;101(6):1416-1422
pubmed: 27391195
Transplantation. 2007 Dec 27;84(12 Suppl):S17-9
pubmed: 18162980
Clin Transplant. 2015 Mar;29(3):268-76
pubmed: 25644963
Am J Transplant. 2006 Aug;6(8):1841-7
pubmed: 16780546
Lancet. 2019 May 18;393(10185):2059-2072
pubmed: 31006573
Am J Transplant. 2017 Feb;17(2):542-550
pubmed: 27529836
Nephrol Dial Transplant. 2011 Dec;26(12):4124-31
pubmed: 21622990
Clin Transplant. 2010 Jul;24 Suppl 22:16-21
pubmed: 20590688
Clin Rev Allergy Immunol. 2020 Feb;58(1):92-106
pubmed: 31183788
Am J Transplant. 2021 Nov;21(11):3649-3662
pubmed: 34101982
Transpl Int. 2017 Sep;30(9):874-883
pubmed: 28403566
Am J Transplant. 2017 Jan;17(1):115-128
pubmed: 27343838
BMJ. 2019 Sep 17;366:l4923
pubmed: 31530561
Transplantation. 2017 Jun;101(6):1433-1440
pubmed: 27495772

Auteurs

Pierre Guy (P)

Department of Nephrology and Organ Transplantation, Centre Hospitalier et Universitaire (CHU), Toulouse, France.

Audrey Delas (A)

Department of Pathology, Toulouse University Hospital, Toulouse, France.

Laure Esposito (L)

Department of Nephrology and Organ Transplantation, Centre Hospitalier et Universitaire (CHU), Toulouse, France.

Olivier Cointault (O)

Department of Nephrology and Organ Transplantation, Centre Hospitalier et Universitaire (CHU), Toulouse, France.

Magali Colombat (M)

Department of Pathology, Toulouse University Hospital, Toulouse, France.
Centre Hospitalier et Universitaire, Université Paul Sabatier Toulouse III, Toulouse, France.

Nicolas Congy-Jolivet (N)

Laboratory of Immunology, Biology Department, Centre Hospitalier et Universitaire (CHU) de Toulouse, Toulouse, France.

Marc Raynaud (M)

Paris Translational Research Epidemiology and Biostatistics Department, Université de Paris, INSERM U970, PARCC, Paris, France.

Nassim Kamar (N)

Department of Nephrology and Organ Transplantation, Centre Hospitalier et Universitaire (CHU), Toulouse, France.
Centre Hospitalier et Universitaire, Université Paul Sabatier Toulouse III, Toulouse, France.
Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1043-CNRS 5282, Toulouse, France.

Arnaud Del Bello (A)

Department of Nephrology and Organ Transplantation, Centre Hospitalier et Universitaire (CHU), Toulouse, France.
Centre Hospitalier et Universitaire, Université Paul Sabatier Toulouse III, Toulouse, France.
Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1043-CNRS 5282, Toulouse, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH